All regulatory updates
493 results found
AICIS varies AIIC listings after evaluation for multiple textile dye/printing ink chemicals, adding/amending SIRs with 20-working-day notification triggers
AICIS issued an inventory notice varying AIIC listing terms after evaluation for CAS 70693-64-0, 12222-80-9, 15141-18-1, 68516-81-4, 69766-79-6, and 72987-42-9. The variations include new SIRs and an amended SIR requiring introducers to notify AICIS of volume introduced and end use within 20 working days when specified conditions occur (e.g., end use changes beyond textile dyes/printing inks, use by non-professional workers, start of manufacturing, volume-related conditions, or new adverse environmental effects information—conditions vary by CAS). Compliance teams should map each CAS to its listing conditions and implement processes to detect trigger events and meet the 20-working-day notification timeframe.
AICIS varies AIIC listing after evaluation for CAS 3253-39-2, adding a Specific Information Requirement (SIR) with 20-working-day notification triggers
AICIS issued an inventory notice varying the Australian Inventory of Industrial Chemicals (AIIC) listing terms for CAS 3253-39-2 to add a Specific Information Requirement (SIR). The SIR requires introducers to notify the Executive Director about volume introduced and end use within 20 working days if the chemical is introduced for consumer end use (except articles). Compliance teams should review product end-use classifications and ensure internal triggers and recordkeeping support the 20-working-day reporting timeline when consumer end use occurs or changes.
EPA extends postponement of effectiveness for certain TSCA risk management provisions for trichloroethylene (TCE) until May 18, 2026
EPA published a final action extending the postponement of effectiveness for certain provisions of the TSCA risk management rule for trichloroethylene (TCE), specifically affecting conditions tied to TSCA section 6(g) exemptions, until May 18, 2026. This changes the timeline for when affected requirements become effective for entities relying on (or managing) exempted uses under the TCE rule. Compliance teams should reassess implementation schedules, contractual obligations, and operational controls tied to the postponed provisions.
EPA extends postponement of effectiveness for certain trichloroethylene (TCE) TSCA risk management provisions (TSCA §6(g) exemption conditions) until May 18, 2026
EPA published a Federal Register rule extending the postponement of effectiveness for certain provisions related to conditions imposed on TSCA §6(g) exemptions in the 2024 TSCA trichloroethylene (TCE) risk management rule. The postponement was extended so that, as of Feb. 17, 2026, the affected provisions are postponed until May 18, 2026. Companies relying on, seeking, or operating under TSCA §6(g) exemptions associated with the TCE rule should adjust compliance planning to the updated timeline and monitor for subsequent changes.
European Commission updated CRA “Reporting obligations” page with SRP reporting mechanics and timelines (early warning/notifications/final report)
The European Commission updated its CRA “Reporting obligations” policy page (last update shown as 16 February 2026). While not amending Annex I text, the page provides official, practical clarification of CRA reporting mechanics tied to vulnerability handling (closely linked to Annex I baseline/essential requirements around vulnerability handling and lifecycle security). It summarizes expected reporting timelines (e.g., early warning within 24 hours, notification within 72 hours, and final report deadlines) and references the Single Reporting Platform (SRP) framework and related delegated act context for CSIRTs withholding notifications. Compliance teams can use this as an authoritative reference for setting up incident/vulnerability reporting processes aligned with CRA expectations.
European Commission updates CRA reporting obligations page with operational incident/vulnerability reporting timelines and references delegated act on CSIRT dissemination delays
The European Commission updated its official CRA “Reporting obligations” page (last update shown: 16 February 2026). The update provides operational details that compliance teams can use to implement vulnerability-handling and reporting processes linked to CRA Annex I Part II (vulnerability handling), including: (1) reporting applicability date for actively exploited vulnerabilities and severe incidents (stated as applying as of 11 September 2026); (2) expected notification sequencing/timelines (early warning within 24 hours; full notification within 72 hours); and (3) final report timing (≤14 days after corrective measure is available for actively exploited vulnerabilities; within a month for severe incidents). The page also points to an EU delegated act adopted on 11 December 2025 related to circumstances under which CSIRTs may delay dissemination, which is relevant for organizations designing reporting workflows via the Single Reporting Platform ecosystem. This is not an Annex I text amendment, but an authoritative Commission implementation/guidance update affecting how Annex I-linked processes are operationalized.
ECHA confirms February 2026 Candidate List update: ad hoc MSC working group established for Article 57(f) ‘equivalent level of concern’ SVHC cases
ECHA reported outcomes from the February 2026 Member State Committee (MSC) meeting, including establishment of an ad hoc working group and adoption of its mandate to address SVHC identifications based on ‘equivalent level of concern’ under REACH Article 57(f). This is a procedural/governance development relevant to how future SVHC identifications (especially non-CMR/PBT/vPvB cases) may be assessed and progressed, which can affect compliance monitoring and forward-looking SVHC pipeline risk assessment.
ECHA Member State Committee establishes ad hoc working group on SVHC “equivalent level of concern” (Article 57(f)) cases
ECHA’s Member State Committee (MSC) established an ad hoc working group on SVHC identifications based on an “equivalent level of concern” under REACH Article 57(f) and adopted its mandate. This is a procedural/governance development relevant to the REACH SVHC identification process (not a Candidate List addition itself), and may affect how Article 57(f) SVHC proposals are assessed/handled going forward. Compliance teams should monitor subsequent MSC outputs for potential impacts to SVHC identification criteria, consistency of decisions, and prioritisation signals for future Candidate List additions.
Illinois SB1773 proposal would add xylazine as a Class III controlled substance and establish enumerated xylazine exemptions (Senate Committee Amendment No. 4)
Per the official ILGA bill record, SB1773 proposes to amend the Illinois Controlled Substances Act to add xylazine as a Class III controlled substance (effective date stated in the bill synopsis as January 1, 2026). The ILGA full-text for Senate Committee Amendment No. 4 includes a new Section 720 ILCS 570/309.1 (‘Xylazine exemptions’) specifying circumstances where xylazine ‘shall not be considered a controlled substance’ (e.g., certain FDA-approved/permitted animal-drug uses by licensed Illinois veterinarians, API manufacturing for approved animal drugs, use by certified euthanasia technicians employed by certified euthanasia agencies, and wildlife biologist fieldwork under indirect veterinary supervision). Compliance teams should treat this as a pending change until enacted, but should assess potential impacts on controlled-substance controls and professional-use carve-outs for xylazine in Illinois if the bill becomes law.
ECHA Member State Committee establishes ad hoc working group for SVHC ‘equivalent level of concern’ (Article 57(f)) cases
ECHA published meeting highlights stating the Member State Committee (MSC) established an ad hoc working group and adopted its mandate to address SVHC identification under the Article 57(f) ‘equivalent level of concern’ route. This is a process/governance development that may influence how future SVHC dossiers are assessed and how ‘equivalent concern’ justifications are handled, affecting companies monitoring potential SVHC identification for substances not fitting standard hazard endpoints.
ECHA Member State Committee establishes ad hoc working group on SVHC “equivalent level of concern” (Article 57(f)) cases
ECHA’s Member State Committee (MSC) established an ad hoc working group focused on SVHC identification under the “equivalent level of concern” pathway (REACH Article 57(f)). This is a governance/interpretation process step that can influence future SVHC identifications beyond CMR, PBT, and vPvB criteria, and is relevant for compliance teams monitoring pipeline signals for potential Candidate List additions.
Illinois SB1773 legislative status update: placed on House Calendar for 2nd Reading (Short Debate)
The Illinois General Assembly status record for SB1773 shows the bill’s latest action as of 2/13/2026: ‘House: Placed on Calendar 2nd Reading – Short Debate.’ This is a legislative progress update indicating the proposal to amend the Illinois Controlled Substances Act (including xylazine scheduling and related provisions) remains pending and has not been shown as enacted on the ILGA status page. Compliance teams tracking potential controlled-substance handling, distribution, and professional-use exceptions in Illinois should monitor for subsequent House action and any enactment (Public Act) before treating requirements as in force.
Illinois SB1773 advances in House: placed on Calendar 2nd Reading (Short Debate)
Illinois SB1773 (104th General Assembly), which would amend the Illinois Controlled Substances Act to classify xylazine as a Class/Schedule III controlled substance and include specific statutory exemptions for certain veterinary/animal-drug and professional uses, advanced procedurally in the Illinois House. The ILGA bill status record shows the bill was placed on the House Calendar for 2nd Reading (Short Debate) on 2026-02-13. This is legislative progress and not enactment; compliance teams should treat the requirements as pending and monitor for passage, signature, and any finalized effective/implementation dates.
AICIS adds CAS 3113590-25-0 to the Australian Inventory of Industrial Chemicals (AIIC) 5 years after assessment certificate (s 82)
AICIS published an Inventory notice that an industrial chemical (CAS 3113590-25-0; 1-Pyrrolidinepropanaminium, N,N,N-trimethyl-2,5-dioxo-, 3-polyisobutenyl derivs., Me sulfates) was added to the Australian Inventory of Industrial Chemicals under section 82 of the Industrial Chemicals Act 2019 (addition 5 years after issue of an assessment certificate). The notice also reiterates that specific information requirement (SIR) obligations apply and introducers must notify AICIS within 28 days if their introduction circumstances differ from those described in AICIS’s assessment—relevant for ongoing compliance, record-keeping, and change management for import/manufacture conditions.
EPA proposed amendments to TSCA Title VI formaldehyde emission standards (add ISO 12460-2:2024 QC option; update incorporated standards)
EPA proposed amendments to the TSCA Title VI Formaldehyde Emission Standards for Composite Wood Products. The proposal would add ISO 12460-2:2024(en) (small-scale chamber method) as an additional quality control test method for measuring formaldehyde emissions and update incorporation-by-reference to current versions of voluntary consensus standards. Compliance teams for composite wood product manufacturers, importers, fabricators, certifiers, and third-party labs should review the proposed test-method/standard updates and submit comments by the stated deadline, as adoption would affect testing, certification, and documentation practices under TSCA Title VI.
Illinois HB5046 introduced to amend 720 ILCS 570/311.6 on e-prescribing exceptions and pharmacy transfer/notification when initial e-prescription cannot be filled
Illinois HB5046 (104th General Assembly) was introduced on 2026-02-10 and proposes amendments impacting 720 ILCS 570/311.6 (electronic prescribing for Schedule II–V controlled substances). As described in the bill text, it would (1) require a dispenser/pharmacy that cannot fill an initial electronically received prescription due to out-of-stock conditions to immediately contact the patient and ask whether the prescription should be electronically transferred to a pharmacy of the patient’s choosing (consistent with 21 CFR 1306), and (2) expand/clarify exceptions to mandatory electronic prescribing where drugs may need to be filled outside typical retail hours or are difficult to obtain due to drug shortages/inventory limitations. The bill also contains conforming changes to the Pharmacy Practice Act (225 ILCS 85/19). Compliance teams at pharmacies, health systems, and prescriber organizations should monitor this bill because it would change operational workflows for patient communication and prescription transfer, and would adjust when non-electronic prescribing is permitted for controlled substances.
Nevada Board of Pharmacy agenda posts workshop materials for proposed Schedule I additions: N‑pyrrolidino metonitazene and N‑pyrrolidino protonitazene (NAC 453.510)
The Nevada State Board of Pharmacy posted a first amended agenda (posted Feb 10, 2026) for its March 5, 2026 meeting that includes a workshop item and embedded proposed regulatory text to amend NAC 453.510 (Schedule I) to add the nitazene analogs N‑pyrrolidino metonitazene and N‑pyrrolidino protonitazene. If adopted through the Board’s rulemaking process, these substances would be treated as Schedule I controlled substances in Nevada, triggering associated controlled-substance controls (e.g., prohibitions/limitations on possession and handling, and compliance program updates for registrants).
Illinois HB5046 introduced to modify electronic prescribing of controlled substances requirements (out-of-stock transfer workflow and expanded exceptions)
Illinois HB5046 (104th General Assembly) was introduced to amend 720 ILCS 570/311.6 (electronic prescribing of Schedule II–V controlled substances). As described in the research text, the proposal would require a dispenser/pharmacy that cannot fill an initially received electronic controlled-substance prescription due to being out of stock to immediately contact the patient and offer to electronically transfer the prescription to a pharmacy of the patient’s choosing (consistent with 21 CFR 1306). It would also add/clarify exceptions where a prescriber is not required to e-prescribe when timely access is impractical, including when filling may need to occur outside typical retail pharmacy hours or when drug shortages/inventory limitations apply. Compliance impact: pharmacy workflow changes, patient notification/transfer procedures, and prescriber documentation/decisioning around EPCS exceptions.
CARB updates SB 261 docket page (Updated 2/10/26) detailing voluntary submission mechanics and docket window
CARB updated its SB 261 public docket page (marked Updated 2/10/26) to restate its current operational posture during the injunction period and to provide practical instructions for voluntary submissions (e.g., submitting a company statement and a public link to the SB 261 report hosted on the entity’s website). The page also describes administrative handling, including an indicated review timeline before public release and a stated docket submission window (Dec 1, 2025 to Jul 1, 2026). This update is operationally important for entities choosing to submit voluntarily while enforcement is stayed.
CARB maintains SB 261 voluntary reporting docket and instructions while enforcement is enjoined (page updated Feb. 10, 2026)
CARB’s SB 261 docket page was updated (noted as Updated 2/10/26) and continues to provide operational instructions for covered entities that voluntarily submit climate-related financial risk reports while SB 261 enforcement is paused due to a Ninth Circuit injunction. The docket materials describe how to submit a report link/attestation, review/processing timelines, and where approved submissions are posted. Compliance teams should treat this as the current CARB-endorsed process for voluntary submissions and monitoring of SB 261 implementation posture pending litigation outcomes.